Medtronic PLC (NYSE:MDT) Announces $0.72 Quarterly Dividend
Medtronic PLC (NYSE:MDT) has announced a quarterly dividend of $0.72 per share, payable on October 16th to shareholders of record on September 25th. This translates to an annualized payout of $2.88 and a 3.1% yield. The company boasts a 49-year history of dividend increases and its dividend is well-covered by earnings, with a current payout ratio of 47.8% and a projected future payout ratio of 45.1%.
34,434 Shares in Medtronic PLC $MDT Acquired by Trust Co. of Vermont
Trust Co. of Vermont recently acquired 34,434 shares of Medtronic PLC (NYSE:MDT) valued at approximately $2.7 million during the second quarter. This move comes as institutional investors and hedge funds now collectively own 82.06% of the company. Medtronic also reported strong quarterly results, beating analyst expectations with $9.81 billion in revenue and $1.55 earnings per share, while maintaining a "Moderate Buy" consensus rating and declaring a $0.72 per share quarterly dividend.
Medtronic PLC $MDT Stock Holdings Increased by OneDigital Investment Advisors LLC
OneDigital Investment Advisors LLC significantly increased its stake in Medtronic PLC (NYSE:MDT) by 30.6% in the second quarter, bringing its total holdings to 144,697 shares valued at $11.32 million. Other institutional investors also adjusted their positions in Medtronic. The article also details recent analyst ratings, financial performance, a declared dividend, and insider trading activity for the medical technology company.
Continuum Advisory LLC Reduces Position in Medtronic PLC $MDT
Continuum Advisory LLC significantly reduced its stake in Medtronic PLC (NYSE:MDT) by 87.9% in the second quarter, now holding 6,055 shares valued at $474,000. Despite this, other institutional investors have increased their positions. Analysts maintain a "Moderate Buy" rating for Medtronic, with a consensus target price of $98.83, and the company recently declared a quarterly dividend of $0.72 per share.
Deutsche Bank AG Trims Holdings in Medtronic PLC $MDT
Deutsche Bank AG has reduced its stake in Medtronic PLC by 2.9% during the second quarter, selling 552,537 shares and now owning 18,449,877 shares valued at over $1.44 billion. Despite this, other institutional investors like Brighton Jones LLC and HUB Investment Partners LLC increased their holdings. Medtronic recently reported strong quarterly earnings, beating analyst estimates, and declared a quarterly dividend of $0.72 per share.
Global Retirement Partners LLC Invests $4.62 Million in Medtronic PLC $MDT
Global Retirement Partners LLC invested $4.62 million in Medtronic PLC, acquiring 59,031 shares during the second quarter. Medtronic reported strong quarterly earnings, beating expectations with $1.55 EPS and $9.81 billion in revenue, representing a 9.9% year-over-year increase. Analysts maintain a "Moderate Buy" rating with an average price target of $98.83, and the company announced a quarterly dividend of $0.72 per share, yielding 3.1% annually.
BlackRock Inc. Acquires 838,220 Shares of Medtronic PLC $MDT
BlackRock Inc. increased its stake in Medtronic PLC by 838,220 shares in the second quarter, bringing its total holdings to 114.02 million shares valued at $8.92 billion. Medtronic reported strong quarterly revenues of $9.81 billion and adjusted earnings of $1.55 per share, exceeding analyst expectations, and declared a quarterly dividend of $0.72 per share. Analysts generally maintain a "Moderate Buy" rating for Medtronic, with an average price target of $98.83.
Is Cooper Companies (COO) Cheap After Slower Growth Forecasts Raised Valuation Concerns?
Cooper Companies (COO) is considered 5.5% undervalued with a fair value estimate of $80.57, trading at $76.16. The company is expected to see substantial revenue growth from its MyDAY contact lens rollout. However, the stock faces risks from slower MyDAY adoption or weakness in its fertility and Paragard IUD segments, and its P/E ratio of 63x is significantly higher than the industry average of 28x, indicating potential valuation risk.
Is Intuitive Surgical’s New Malaysia Plant a Subtle Shift in ISRG’s Global Growth Strategy?
Intuitive Surgical plans to open a new manufacturing facility in Penang, Malaysia, by 2028 to produce instruments and electromechanical devices for its da Vinci surgical system. This expansion aims to enhance supply resilience and regional access within Asia Pacific, supporting the company's long-term growth by aligning with increasing demand for robotic-assisted surgery in the region. While this move does not significantly alter the immediate focus on procedure volumes and managing product recalls, it strategically positions Intuitive Surgical to capitalize on future demand and mitigate risks like rising tariffs in Asia.
Did Abbott’s Q2 Beat and Profit Hike Just Shift Abbott Laboratories’ (ABT) Investment Narrative?
Abbott Laboratories (ABT) reported stronger-than-expected fiscal Q2 results in August 2026, raising its annual profit forecast due to strong demand for cancer diagnostics and medical devices. This outperformance reinforces the company's diversified healthcare portfolio as a key driver, despite ongoing risks like competition in continuous glucose monitoring. The article discusses how this beat and upgraded outlook affect ABT's investment narrative, including its partnership with Google Health, and its projected revenue and earnings growth towards a $119.12 fair value.
Medtronic to Pay Quarterly Dividend of $0.72 a Share, Payable Oct. 16 to Holders of Record Sept. 25
Medtronic plc announced it will pay a quarterly dividend of $0.72 per share. The dividend is payable on October 16 to shareholders of record as of September 25. The medical equipment company also shared recent news, including receiving a Health Canada Licence for its Affera Mapping and Ablation System.
Medtronic announces cash dividend for second quarter of fiscal year 2027
Medtronic plc has announced a cash dividend of $0.72 per ordinary share for the second quarter of fiscal year 2027, consistent with an increase announced in June 2026. The dividend is payable on October 16, 2026, to shareholders of record by September 25, 2026. Medtronic is noted as an S&P 500 Dividend Aristocrat, having increased its annual dividend for 49 consecutive years.
Medtronic announces cash dividend for second quarter of fiscal year 2027
Medtronic plc announced that its board of directors approved a cash dividend of $0.72 per ordinary share for the second quarter of fiscal year 2027. This declaration is consistent with a dividend increase announced in June 2026. Medtronic is noted as an S&P 500 Dividend Aristocrat, having increased its annual dividend for 49 consecutive years.
Medtronic PLC stock outperforms competitors despite losses on the day
Medtronic PLC (MDT) shares decreased by 1.94% to $92.30, breaking a two-day winning streak, on a day when the broader market also saw losses. Despite the decline, the stock still managed to outperform its competitors. The S&P 500 Index fell 0.87% and the Dow Jones Industrial Average fell 1.32%.
Stryker (SYK) Secured A $100 Million Contract, Is The Upside Already Priced In?
Stryker (SYK) recently secured a US$100 million contract modification from the US Defense Logistics Agency, which boosted its stock by around 2.7%. While Simply Wall St's narrative valuation suggests the stock is 12.1% undervalued at $386.80, a P/E ratio analysis indicates investors are already paying a premium compared to the industry and peers. The article advises investors to carefully weigh both the potential upsides and risks before making investment decisions, given the mixed signals on its valuation.
Medtronic: Expecting Strong Revenue Growth In Fiscal Q1 (NYSE:MDT)
Medtronic (NYSE: MDT) is rated as a "Buy" due to strong Q4 organic revenue growth, particularly in Cardiovascular and Diabetes segments, and attractive valuation. The company provided optimistic FY 2027 guidance targeting significant organic revenue growth and non-GAAP EPS despite market headwinds. Technical analysis indicates improving trends, with clear resistance and support levels.
Orchestra BioMed to Participate in the Wells Fargo 21st Annual Healthcare Conference
Orchestra BioMed announced that its Chairman and CEO, David Hochman, will present at the Wells Fargo 21st Annual Healthcare Conference on September 10, 2026, and will also hold one-on-one investor meetings. The company is advancing two key product candidates: AVIM Therapy for hypertension and Virtue® Sirolimus AngioInfusion™ Balloon for atherosclerotic artery disease, both of which are undergoing pivotal clinical trials. A live webcast of the presentation will be available on the company's Investor Relations website.
Global Cardiovascular Devices Market to Reach $101.6 Billion by 2030, Says BCC Research Analyst
The global cardiovascular devices market is projected to grow from $72.4 billion in 2025 to $101.6 billion by 2030, driven by an aging population, increased disease prevalence, and advancements in minimally invasive procedures and remote monitoring. Key trends include the adoption of leadless pacemakers, pulsed field ablation, and AI-enabled cardiac monitoring solutions. Major players like Abbott, Boston Scientific, and Medtronic dominate the market, while innovators introduce next-generation implantable and bioresorbable devices.
Mitsubishi UFJ Trust & Banking Corp Reduces Holdings in Medtronic PLC $MDT
Mitsubishi UFJ Trust & Banking Corp significantly reduced its stake in Medtronic PLC by 9.9% in the second quarter, selling over 64,000 shares. Despite this reduction, institutional investors collectively own a large portion of Medtronic, and analysts generally maintain a "Moderate Buy" rating for the company. Medtronic reported solid quarterly revenue and earnings, increased its dividend, but faces potential legal challenges and recent insider selling.
Medtronic PLC $MDT Shares Sold by HighTower Advisors LLC
HighTower Advisors LLC significantly reduced its stake in Medtronic PLC (NYSE:MDT) by 70.3% in the second quarter, selling 929,333 shares and retaining 393,328 shares valued at $30.8 million. Despite this, institutional investors and hedge funds still own 82.06% of Medtronic's stock. The medical technology company recently exceeded quarterly earnings expectations, reported a 9.9% revenue increase, and raised its quarterly dividend to $0.72 per share, maintaining a "Moderate Buy" rating from analysts, though it faces potential legal uncertainty.
Medtronic PLC $MDT Shares Purchased by Mosaic Family Wealth Partners LLC
Mosaic Family Wealth Partners LLC significantly increased its stake in Medtronic PLC (NYSE:MDT) by 277.4% in the second quarter, bringing its total holdings to 30,717 shares valued at $2.4 million. Medtronic reported strong quarterly earnings, exceeding expectations with $1.55 EPS and $9.81 billion in revenue, leading analysts to maintain a "Moderate Buy" rating with an average price target of $98.83, despite some recent target reductions. The company also raised its quarterly dividend to $0.72 per share and is nearing its 50th consecutive year of dividend increases, though it faces potential legal risks and recent insider selling.
GSA Capital Partners LLP Raises Stake in Medtronic PLC $MDT
GSA Capital Partners LLP significantly increased its stake in Medtronic PLC (NYSE:MDT) by 1,112.5% during the second quarter, bringing its total holdings to 68,541 shares valued at $5.36 million. Medtronic recently exceeded quarterly earnings and revenue expectations, and raised its quarterly dividend to $0.72 per share, offering a 3.1% yield. Analysts generally maintain a "Moderate Buy" rating with an average price target of $98.83, despite some risks such as potential legal action and continued insider selling.
Colrain Capital LLC Has $10.45 Million Position in Medtronic PLC $MDT
Colrain Capital LLC increased its stake in Medtronic PLC by 26.1% in the second quarter, now holding 132,354 shares valued at $10.45 million. Institutional investors collectively own 82.06% of Medtronic, which has a consensus "Moderate Buy" rating. The company recently exceeded earnings expectations, raised its dividend, but faces some analyst target reductions and insider selling.
Medtronic PLC $MDT Shares Purchased by CORDA Investment Management LLC.
CORDA Investment Management LLC increased its stake in Medtronic PLC (NYSE:MDT) by 9.0% in the second quarter, acquiring an additional 24,604 shares, bringing its total holdings to 296,967 shares valued at $23.2 million. Other institutional investors also adjusted their positions in Medtronic, which recently reported strong quarterly earnings, exceeding expectations with $1.55 EPS and $9.81 billion in revenue. The company maintains a "Moderate Buy" consensus rating from analysts, raised its quarterly dividend to $0.72 per share, marking 49 consecutive years of dividend increases, but faces risks from insider selling and a potential injunction in an Applied Medical case.
Merit Medical names Sheri Lewis as global operations chief
Merit Medical Systems, Inc. announced the appointment of Sheri Lewis as Executive Vice President of Global Operations, effective August 31, 2026. Lewis brings 30 years of experience in global operations, manufacturing, and supply chain management. The current Chief Operating Officer, Neil Peterson, will transition to a Senior Advisor role before completing over 32 years of service with the company on March 5, 2027.
Intuitive Surgical (ISRG), What Is Behind The Fresh Attention?
Intuitive Surgical (ISRG) is garnering renewed interest following announcements of a new manufacturing facility in Malaysia, My Intuitive+ renewals, and updates to its da Vinci 5 platform. Despite a recent 30-day stock rebound of 12.61%, the year-to-date share price has declined by 29.23%. The article discusses differing valuation perspectives, with a narrative suggesting the stock is 36.9% undervalued at $630.48, contrasting with market multiples indicating a premium valuation with a P/E of 44.8x.
How Merit’s Leadership Transition in Global Operations at Merit Medical Systems (MMSI) Has Changed Its Investment Story
Merit Medical Systems (MMSI) recently appointed Sheri Lewis as Executive Vice President of Global Operations, bringing extensive experience to the role. This leadership change is expected to support operational execution and supply chain resilience, rather than immediately altering the investment narrative around key risks like tariffs or reimbursement. Investors will be watching how her expertise helps the company meet its raised 2026 revenue guidance while navigating ongoing challenges.
How Tandem’s Q2 Loss and Pharmacy Pivot Will Impact Tandem Diabetes Care (TNDM) Investors
Tandem Diabetes Care (TNDM) reported a Q2 2026 net loss of US$21.17 million despite sales of US$254.56 million, while reaffirming full-year sales guidance of US$1.07 billion to US$1.09 billion. The company is pivoting towards pharmacy-based pump distribution and new insulin delivery technologies, a strategic shift that could impact its revenue generation and long-term earnings profile. Investors are advised to consider the potential of this pharmacy expansion against competitive risks and shifting reimbursement terms.
Merit Medical names Sheri Lewis as global operations chief By Investing.com
Merit Medical Systems, Inc. (NASDAQ:MMSI) has appointed Sheri Lewis as Executive Vice President of Global Operations, effective August 31, 2026. Lewis brings 30 years of experience from previous senior roles at companies like Medtronic and Honeywell. This appointment follows current COO Neil Peterson's transition to a Senior Advisor role before his retirement in March 2027.
Merit Medical Announces Global Operations Leadership Transition
Merit Medical Systems, Inc. announced that Sheri Lewis will join as Executive Vice President of Global Operations, effective August 31, 2026. Ms. Lewis brings three decades of experience in global operations, manufacturing, and supply chain management from various senior roles. Neil Peterson, the current Chief Operating Officer, will transition to a Senior Advisor role to ensure a smooth handover and will complete his 32 years of service to Merit in March 2027.
Tenet Healthcare (NYSE:THC) Stock Price
Tenet Healthcare (NYSE:THC) is currently trading at US$268.52, with a fair value estimate of US$250, indicating it is overvalued by 7.4%. Analyst narratives provide varying perspectives, with some highlighting growth drivers like behavioral care and outpatient trends, while others caution about M&A risks and Medicaid reliance. Recent insider transactions show net selling activity.
After more than 32 years, Merit Medical's chief operating officer will become a senior adviser
Merit Medical Systems (NASDAQ: MMSI) has announced a leadership transition in its global operations. Sheri Lewis will join as Executive Vice President of Global Operations, bringing 30 years of experience, while current COO Neil Peterson will transition to Senior Advisor before concluding his 32-year tenure with the company. This move aims to support continuity and strategic growth.
Merit Medical Announces Global Operations Leadership Transition
Merit Medical Systems, Inc. announced that Sheri Lewis will join the company as Executive Vice President of Global Operations, effective August 31, 2026. Ms. Lewis brings extensive experience from previous senior roles in global operations, manufacturing, and supply chain management. Neil Peterson, current Chief Operating Officer, will transition to a Senior Advisor role to ensure a smooth handover before completing his 32-year tenure with Merit Medical on March 5, 2027.
Abbott Laboratories (ABT) Could Be 5% Undervalued Following MiniMed Pump Launch
Abbott Laboratories (ABT) is considered 5.4% undervalued, trading at $112.68 against a fair value estimate of $119.13. This comes amidst renewed investor interest following MiniMed's U.S. launch of its app-controlled Flex insulin pump, integrating Abbott’s Instinct continuous glucose sensor. Analysts project ABT's earnings to reach $9.5 billion by July 2029, up from $5.4 billion today, but warn of potential headwinds from pricing pressure in diagnostics and foreign exchange fluctuations.
Medtronic PLC stock outperforms competitors on strong trading day
Medtronic PLC (MDT) shares rose 2.22% to $94.13 on a strong trading day for the stock market, outperforming the S&P 500 Index and the Dow Jones Industrial Average. This marks the second consecutive day of gains for the stock.
Is IART Still Attractive as Its Low Valuation Meets Execution Risks?
Integra LifeSciences Holdings Corp. (IART) trades at a significant valuation discount compared to its industry and market benchmarks, driven by recent margin gains and improved operating execution. However, the company faces challenges including modest revenue growth, elevated leverage, and unresolved regulatory remediation with the FDA. Despite these risks, Integra's operational improvements and cost savings offer support for its earnings outlook, making execution crucial for its investment appeal.
AdaptHealth Breach Exposed Health Records of One in 13 Vermonters
A data breach at AdaptHealth, a durable medical equipment provider, exposed the health records of 48,090 Vermonters, representing about one in 13 residents. This incident accounts for 57% of all Vermonters affected by data breaches reported to the state Attorney General's Office since April 2026. The breach, attributed to social engineering targeting a third-party contractor's account, allowed access to patient management systems and electronic health record portals.
Johnson and Johnson stock hits all-time high at 275.48 USD
Johnson & Johnson (JNJ) stock has reached an all-time high of $275.48 USD, pushing its market capitalization to $661 billion, driven by a 53.01% increase over the last year. InvestingPro data indicates a 1-year total return of 56.29% and a P/E ratio of 31.37, with the company consistently raising dividends for 55 years despite appearing overvalued. Recent analyst updates from Guggenheim, Raymond James, and Freedom Capital have raised price targets, citing strong quarterly performance and FDA approvals for new platforms like the Ottava robotic surgery system.
Todd Asset Management LLC Cuts Stock Holdings in Medtronic PLC $MDT
Todd Asset Management LLC reduced its stake in Medtronic PLC by 8.7% in the second quarter, selling over 81,000 shares but still holding 849,171 shares valued at $66.4 million. Despite the reduction, Medtronic reported strong quarterly earnings of $1.55 per share and $9.81 billion in revenue, exceeding expectations and leading to a dividend increase. The company maintains a "Moderate Buy" consensus rating from analysts, with institutional investors owning a significant 82.06% of its stock.
Veritas Asset Management LLP Has $7.56 Million Stock Holdings in Medtronic PLC $MDT
Veritas Asset Management LLP has reduced its stake in Medtronic PLC by 40.6% in the second quarter, now holding 96,690 shares valued at $7.56 million. Despite this reduction, other institutional investors have increased their positions. Medtronic reported strong quarterly earnings, beating estimates with $1.55 EPS and $9.81 billion in revenue, and raised its quarterly dividend to $0.72 per share.
Principal Financial Group Inc. Sells 228,558 Shares of Medtronic PLC $MDT
Principal Financial Group Inc. has reduced its stake in Medtronic PLC (NYSE:MDT) by 9.6%, selling 228,558 shares but still retaining 2.15 million shares valued at $168.3 million. Medtronic recently reported strong quarterly earnings, beating analyst estimates, and increased its quarterly dividend. Analyst sentiment is cautiously positive with a "Moderate Buy" consensus, despite some recent price target reductions.
Medtronic PLC $MDT Position Reduced by Hedeker Wealth LLC
Hedeker Wealth LLC reduced its stake in Medtronic PLC (NYSE:MDT) by 36.6% in the second quarter, selling 17,444 shares and retaining 30,282 shares valued at $2,369,000. Other institutional investors showed mixed activity, with some increasing and others reducing their positions in MDT. Insider activity includes an EVP selling over 4,000 shares, and analysts have issued a "Moderate Buy" consensus rating with a target price of $98.83.
Journey Advisory Group LLC Grows Position in Medtronic PLC $MDT
Journey Advisory Group LLC significantly increased its stake in Medtronic PLC (NYSE:MDT) by 2,312.5% in the second quarter, now owning 62,121 shares valued at $4.901 million. Other institutional investors also adjusted their positions in Medtronic, which has shown mixed sentiment from analysts regarding its valuation and near-term upside. Despite some insider selling and varying price targets, the company recently increased its quarterly dividend and reported stronger-than-expected earnings.
Fifth Third Bancorp Trims Position in Medtronic PLC $MDT
Fifth Third Bancorp reduced its stake in Medtronic PLC by 26.2% in the second quarter, selling 55,387 shares and retaining 155,772 shares valued at $12.2 million. Institutional investors hold 82.06% of Medtronic, which recently reported strong quarterly revenue and adjusted earnings, exceeding analyst expectations. The company also increased its quarterly dividend and maintains a "Moderate Buy" consensus rating from analysts, despite some recent price target adjustments.
Fox Run Management L.L.C. Increases Position in Medtronic PLC $MDT
Fox Run Management L.L.C. significantly increased its stake in Medtronic PLC (NYSE:MDT) by 364.9% in the second quarter, bringing its total holdings to 23,397 shares valued at $1.83 million. Other major institutional investors like Vanguard Group Inc., State Street Corp, and JPMorgan Chase & Co. also boosted their positions in Medtronic. The article also notes mixed sentiment among analysts and institutional investors, with recent news covering both positive aspects like market outperformance and dividend increases, and negative points such as CEO compensation and insider sales.
Medtronic PLC stock underperforms Tuesday when compared to competitors despite daily gains
Medtronic PLC (MDT) stock rallied 1.64% on Tuesday, closing at $92.09, but still underperformed compared to the broader market given that the S&P 500 and Dow Jones Industrial Average both experienced declines. The company's stock finished 13.39% below its 52-week high of $106.33, which was set on November 26th.
NPCE Is Down 12.7% in 3 Months: Is the Pullback a Buying Opportunity?
NeuroPace, Inc. (NPCE) shares have fallen 12.7% in the past three months despite strong performance in its core responsive neurostimulation (RNS) franchise and raised full-year revenue guidance. The decline is attributed to regulatory uncertainty surrounding the FDA's decision on the company's idiopathic generalized epilepsy (IGE) premarket approval supplement. While the RNS business is robust and operating expectations have improved, the IGE setback adds risk, leading to a balanced investment outlook rather than an aggressive buying opportunity.
Oppenheimer Asset Management Inc. Buys 59,676 Shares of Medtronic PLC $MDT
Oppenheimer Asset Management Inc. increased its stake in Medtronic PLC by 11.1%, purchasing 59,676 shares to own a total of 597,429 shares valued at $46.7 million. This comes as institutional investors hold a significant 82.06% of Medtronic's stock. Medtronic recently reported strong quarterly earnings, beating analyst estimates with $1.55 EPS and $9.81 billion in revenue, and increased its quarterly dividend to $0.72.
Qsemble Capital Management LP Has $2.57 Million Position in Medtronic PLC $MDT
Qsemble Capital Management LP significantly increased its stake in Medtronic PLC, raising its position by 507.7% to 32,835 shares valued at $2.57 million. Other institutional investors also adjusted their holdings in Medtronic, which recently reported strong earnings, increased its dividend, and received mixed but generally positive analyst ratings. An executive insider also sold a portion of their shares.
Medtronic PLC $MDT Holdings Increased by Willis Investment Counsel
Willis Investment Counsel increased its stake in Medtronic PLC (NYSE:MDT) by 5.7% during the second quarter, bringing its total holdings to 414,539 shares valued at $32.43 million. This makes Medtronic the 22nd largest holding for the firm, comprising 1.5% of its investment portfolio. Other institutional investors also adjusted their positions in Medtronic, which currently has a consensus rating of "Moderate Buy" and a target price of $98.83 from analysts.
